Pharmaceuticals
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notif...
2021-12-16 21:00
2432
Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting
TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug...
2021-12-16 20:00
2842
Bionomics Limited Announces Pricing of Initial Public Offering in the United States
ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...
2021-12-16 19:00
3329
BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021
Advances in Alzheimer's, innovation in DNA vaccines, increased regulatory collaboration and the evolving impact of Artificial Intelligence, join Covid-19 as key stories and trends of 2021 LONDON, Dec. 16, 2021 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in pr...
2021-12-16 16:14
2831
Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
Dose escalation, monotherapy trial launched to access the safety and
preliminary anti-tumor activity of Debio 0123 in the treatment of advanced
solid tumors
LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2021-12-16 16:00
2525
PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
HEIDELBERG, Germany, and CAMBRIDGE, Mass., Dec. 16, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops ...
2021-12-16 15:00
2690
French Neurosurgeon and Physicist Dr. Alim Louis Benabid, Recipient of 42nd Honda Prize, Honored at Online Award Ceremony
TOKYO, Dec. 16, 2021 /PRNewswire/ -- The Honda Foundation, based in Tokyo, is pleased to announce that the 42nd Honda Prize Award Ceremony was held on Wednesday, November 17, 2021, and awarded this year's prize to Dr. Alim Louis Benabid, emeritus professor at the Joseph Fourier University and chai...
2021-12-16 15:00
1920
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
-- Takeda submits application for TAK-019/NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for NDA, toJapan's Ministry of Health, Labour and Welfare (MHLW) -- Interim data from Phase 1/2 trial in Japan demonstrate robust immune response and favorable tolerability with no serious a...
2021-12-16 12:03
3303
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
* TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults withprimary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 * TARPEYO (developed un...
2021-12-16 08:49
4762
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
* QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, which is approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT) * The Australian launch is a significant ...
2021-12-16 03:58
3374
CSafe Global Announces Acquisition of Softbox Systems to Create the Global Leader in Temperature-Controlled Shipping Solutions
DAYTON, Ohio and LONG CRENDON, Buckinghamshire, England, Dec. 15, 2021 /PRNewswire/ --CSafe Global, the leader in temperature-controlled container solutions for the pharmaceutical industry, announced today that it has acquired Softbox Systems, a provider of passive temperature-controlled packaging...
2021-12-15 22:00
5851
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) ofChina's Na...
2021-12-15 21:00
2097
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio
- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca'...
2021-12-15 16:00
1610
Endurance Longevity Signed Exclusive Licence Agreement to Commercialise Fortacin™ in the Israeli and Balkan regions
HONG KONG, Dec. 15, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) announced that Plethora Solutions Limited (Solutions), a wholly owned subsidiary of the Company has entered into an exclusive ...
2021-12-15 15:01
3370
Red Seal brings New Zealand's #1 best-selling herbal and mineral toothpaste to Pharmaca Integrative Pharmacies, USA
AUCKLAND, New Zealand, Dec. 14, 2021 /PRNewswire/ -- Wednesday 14 December, 2021
, Red Seal is proud to announce their herbal and mineral toothpastes are now
conveniently available at all 28 distinguished Pharmaca stores nationwide.
www.redseal.global/usa
2021-12-15 10:41
2307
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create c...
2021-12-15 09:35
3954
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Everest Medicines
2021-12-15 08:00
4734
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety
SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three ...
2021-12-14 22:04
3115
ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from six st...
2021-12-14 22:04
2810
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...
2021-12-14 18:00
3809
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
7688
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
6026
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5150
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
4931
